Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes

Clinics

Volumn 66, Issue 5, 2011, Pages 793-799

  Machado Neto, João Agostinho ^a   Traina, Fabiola ^a   Lazarini, Mariana ^a   de Melo Campos, Paule ^a   Borgia, Katia ^a   Pagnano, Barbosa ^a   Lorand Metze, Irene ^a   Costa, Fernando Ferreira ^a   Saad, Sara T Olalla ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Acute leukemia; Bone marrow; Hematopoietic disorder; Mutations; Myelodysplasia

Indexed keywords

CD135 ANTIGEN; JANUS KINASE 2; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ARTICLE; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENETIC TESTING; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE;

EID: 79960791227     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000500014     Document Type: Article

References (38)

1. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297-317.
2. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma. 2000;40:1-24 doi: 10.3109/10428190009054877.
3. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932-8.
4. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875-8 doi: 10.1158/1078-0432.CCR-04-2142.
5. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94:455-459.
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61.
7. Lerario AM, Brito LP, Mariani BM, Fragoso MC, Machado MA, Teixeira R. A missense TCF1 mutation in a patient with mody-3 and liver adenomatosis. Clinics. 2009;65:1059-60 doi: 10.1590/S1807-59322010001000024.
8. Torres LC, de Lourdes Lopes Chauffaille M, Delboni TP, Okay TS, Carneiro-Sampaio M, Sugayama S. Rubinstein-taybi syndrome: a female patient with a de novo reciprocal translocation t(2; 16)(q36.3; p13.3) and dysgranulopoiesis. Clinics. 2009;65:107-9 doi: 10.1590/S1807-59322010000100016.
9. Bittencourt PL, Marin ML, Couto CA, Cancado EL, Carrilho FJ, Goldberg AC. Analysis of HFE and non-HFE gene mutations in Brazilian patients with hemochromatosis. Clinics. 2009;64:837-1.
10. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-30 doi: 10.1038/nature04869.
11. Stroud RM, Wells JA. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE. 2004;2004(231):re7 doi: 10.1126/stke.2312004re7.
12. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69-74 doi: 10.1016/S0168-9525(00)89000-9.
13. Muller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate andosteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res. 2007;31:27-32 doi: 10.1016/j.leukres.2006.04.011.
14. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:1441-6 doi: 10.1158/1078-0432.CCR-05-2173.
15. Hafner C, Lopez-Knowles E, Luis NM, Toll A, Baselga E, Fernandez-Casado A, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A. 2007;104:13450-4 doi: 10.1073/pnas.0705218104.
16. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A. 2008;105:2652-7 doi: 10. 1073/pnas.0712169105.
17. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer. 2008;47:363-7 doi: 10.1002/gcc.20540.
18. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program. 2006:240-5.
19. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 1994;91:459-63 doi: 10.1073/pnas.91.2.459.
20. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene. 2007;26:7391-400 doi: 10.1038/sj.onc. 1210549.
21. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776:84.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-99.
23. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51 doi: 10.1182/blood-2009-03-209262.
24. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189-218 doi: 10.1038/sj.leu.2403241.
25. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126:530-3.
26. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105:4792-9, doi: 10.1182/blood-2004-11-4430.
27. Pinheiro RF, de Sa Moreira E, Silva MR, Alberto FL, Chauffaille Mde L. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183:89-93 doi: 10.1016/j.cancergencyto.2008.02.006.
28. Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798-801 doi: 10.1136/jcp.2009.065904.
29. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8 doi: 10.1038/nature03546.
30. Hellstrom-Lindberg E. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. Blood Rev. 2010;24:83-90 doi: 10.1016/j. blre.2010.01.002.
31. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114:3538-45 doi: 10.1182/blood-2009-05-222331.
32. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 2010;95:415-23 doi: 10.3324/haematol.2009.010785.
33. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 2007;110:1025-8 doi: 10.1182/blood-200612-061283.
34. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia. 2006;20:230-8 doi:10.1038/sj.leu.2404057.
35. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006;25:6648-59 doi: 10.1038/sj.onc.1209670.
36. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica.95:819-28 doi: 10.3324/haematol.2009.013797.
37. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009;12:81-9, doi:10.1016/j.drup.2009.04.001.
38. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res. 2010;16:1988-996 doi: 10.1158/1078-0432.CCR-09-2836.